Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0X9WC
|
|||
| Former ID |
DIB006762
|
|||
| Drug Name |
ISIS-DMPK
|
|||
| Drug Type |
Antisense drug
|
|||
| Indication | Myotonic dystrophy [ICD-11: 8C71.0] | Phase 1/2 | [1] | |
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | DMPK messenger RNA (DMPK mRNA) | Target Info | . | [2] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT02312011) A Safety andTolerability Study of Multiple Doses of ISIS-DMPKRx in Adults With Myotonic Dystrophy Type 1. U.S. National Institutes of Health. | |||
| REF 2 | Clinical pipeline report, company report or official report of ISIS Pharmaceuticals. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.